The tests eligible for the collaboration include a quantitative HIV-1 viral load assay, as well as a qualitative test for active infection and early infant diagnosis.
The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.
The method combines array-based DNA synthesis, phage protein display, immunoprecipitation, and high-throughput sequencing.
An array of 15 HIV-1 recombinant protein and associated peptides matched very closely to ELISA results in evaluating the intricacies of associated antibody binding patterns.
The new cartridge-based test runs on the firm's GeneXpert platform and provides a 90-minute molecular diagnosis of HIV in high-risk individuals and infants.
The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The HIV test is the first of several NGS-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The assay is intended for early infant diagnosis of HIV infection.
The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.